Abstract 152P
Background
The detection of copy number alterations (CNAs) is an informative molecular layer in the diagnosis, prognosis, and treatment of lung adenocarcinoma. Traditional tissue biopsies are invasive and often impractical. This study investigates the use of nanopore sequencing on circulating cell-free DNA (cfDNA) as a non-invasive, PCR-free method to detect CNAs in lung adenocarcinoma patients.
Methods
Native cfDNA samples from lung adenocarcinoma patients were analysed using low coverage nanopore sequencing (∼ 1- 3 X). Bioinformatics analysis identified CNAs, which were compared to known CNA patterns in tissue samples. Additionally, tumor fractions were estimated to correlate with tumor stage and aggressiveness.
Results
Nanopore sequencing of cfDNA revealed clinically significant and informative CNAs, including amplifications of 1q (MDM4), chromosome 7 (EGFR) as well as deletion of 8p. These alterations closely mirrored the classic CNA patterns observed in lung adenocarcinoma tissue samples, especially in cfDNA samples derived from patients with progressive cancers (i.e. stage 3-4). The analysis also provided tumor fraction estimates, which correlated with tumor stage and aggressiveness.
Conclusions
This study demonstrates that nanopore sequencing of cfDNA can accurately detect CNAs and estimate tumor fractions, offering a non-invasive alternative to tissue biopsies. This approach holds significant potential for real-time cancer monitoring, prognosis prediction, targeted therapy, and precise cancer subtyping. Estimating tumor fractions is also useful for predicting cancer progression and determining future sequencing coverage and planning.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Renovaro Cube.
Disclosure
K. Roohollahi, E. Post, D. Makarawung, F. van Asch: Financial Interests, Institutional, Stocks/Shares: Renovaro Cube. D. Vessies, J. van den Berg: Financial Interests, Personal, Stocks/Shares: Renovaro Cube.
Resources from the same session
4P - Predicting triple-negative breast cancer molecular subtype from hematoxylin and eosin using deep neural networks
Presenter: Nicola Occelli
Session: Cocktail & Poster Display session
Resources:
Abstract
5P - Onconaut: A precision medicine platform for oncology therapies
Presenter: Altuna Akalin
Session: Cocktail & Poster Display session
Resources:
Abstract
6P - Diagnostic accuracy of artificial intelligence in classifying HER2 status in breast cancer immunohistochemistry slides: A systematic review and meta-analysis
Presenter: Daniel Arruda Navarro Albuquerque
Session: Cocktail & Poster Display session
Resources:
Abstract
8P - Precision medicine drug testing platform to guide the treatment of EML4-ALK fusion lung cancers
Presenter: Sofia Merajver
Session: Cocktail & Poster Display session
Resources:
Abstract
9P - Circulating tumor cells and circulating tumor DNA detection in colorectal cancer stage III patients receiving three or six months of adjuvant treatment
Presenter: Asimina Koulouridi
Session: Cocktail & Poster Display session
Resources:
Abstract
10P - Novel theranostic agents in non-metastatic Egyptian breast cancer patients: miR-96, miR-1275, miR-4317 and miR-744
Presenter: Ahmed Mokhtar
Session: Cocktail & Poster Display session
Resources:
Abstract
11P - A prospective study to evaluate the prognostic implications and molecular mechanism of SLC40A1 gene in primary acute myeloid leukemia
Presenter: Harsh Goel
Session: Cocktail & Poster Display session
Resources:
Abstract
12P - Prognostic value of PD-L1 expression and neutrophil-to-lymphocyte ratio to neoadjuvant chemo-immunotherapy in muscle-invasive urothelial carcinoma patients from the AURA trial
Presenter: Jeremy Blanc
Session: Cocktail & Poster Display session
Resources:
Abstract
13P - Methylation of BRCA1 and RAD51C promoters determined by droplet digital PCR predicts homologous repair deficiency in patients with high-grade serous ovarian cancer: Results of the BOVARY-pilot study in paired FFPE and plasma samples and the ICL ovarian cohort
Presenter: Cassandra Michel
Session: Cocktail & Poster Display session
Resources:
Abstract
14P - SLFN11 detection in patients with small cell lung cancer treated with lurbinectedin: A retrospective translational analysis
Presenter: Daniela Scattolin
Session: Cocktail & Poster Display session
Resources:
Abstract